News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,938 Results
Type
Article (8016)
Company Profile (141)
Press Release (477780)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166750)
Career Advice (305)
Deals (25738)
Drug Delivery (7)
Drug Development (52876)
Employer Resources (14)
FDA (9760)
Job Trends (8574)
News (238197)
Policy (17907)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33156)
ALS (108)
Alzheimer's disease (985)
Antibody-drug conjugate (ADC) (283)
Approvals (10404)
Artificial intelligence (331)
ASCO (159)
Autoimmune disease (220)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6958)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (89)
Bladder cancer (139)
Brain cancer (31)
Breast cancer (518)
Cancer (3751)
Cardiovascular disease (226)
Career advice (245)
Career pathing (1)
CAR-T (178)
CDMO (15)
Celiac Disease (1)
Cell therapy (486)
Cervical cancer (35)
Clinical research (48033)
Collaboration (1276)
Commercialization (3)
Compensation (1530)
Complete response letters (34)
COVID-19 (761)
CRISPR (64)
C-suite (801)
Cystic fibrosis (87)
Data (5842)
Denatured (4)
Depression (106)
Dermatology (67)
Diabetes (353)
Diagnostics (4218)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73748)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88095)
Executive appointments (714)
FDA (12478)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (943)
Gene editing (126)
Generative AI (11)
Gene therapy (331)
GLP-1 (294)
Government (947)
Grass and pollen (2)
Guidances (281)
Healthcare (9367)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (103)
Immuno-oncology (61)
Indications (161)
Infectious disease (953)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (260)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (18)
Liver cancer (45)
Longevity (19)
Lung cancer (537)
Lymphoma (257)
Machine learning (28)
Management (3)
Manufacturing (564)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8676)
Medtech (8833)
Mergers & acquisitions (14407)
Metabolic disorders (725)
mRNA (61)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (226)
Neuropsychiatric disorders (40)
Neuroscience (1865)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (231)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (206)
Parkinson's disease (205)
Partnered (12)
Patents (495)
Patient recruitment (530)
Patient selection (2)
Peanut (32)
People (41354)
Peptides (2)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15517)
Phase 2 (21450)
Phase 3 (14461)
Pipeline (7678)
Policy (18)
Postmarket research (1570)
Preclinical (6553)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (194)
Rare diseases (587)
Real estate (3022)
Recruiting (6)
Regenerative medicine (1)
Regulatory (14943)
Reports (23)
Research institute (584)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (161)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2021)
Stomach cancer (3)
Supply chain (51)
Vaccines (333)
Venture capital (17)
Weight loss (75)
Women's health (87)
Date
Today (65)
Last 7 days (323)
Last 30 days (1418)
Last 365 days (19095)
2026 (13562)
2025 (19252)
2024 (22989)
2023 (26538)
2022 (34594)
2021 (37172)
2020 (33481)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17918)
2015 (24270)
2014 (21680)
2013 (18135)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (229)
Alabama (77)
Alaska (2)
Arizona (309)
Arkansas (11)
Asia (17956)
Australia (2107)
California (12330)
Canada (3228)
China (544)
Colorado (496)
Connecticut (427)
Delaware (214)
Europe (24687)
Florida (1850)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (726)
India (52)
Indiana (323)
Iowa (16)
Japan (421)
Kansas (102)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1229)
Massachusetts (8092)
Michigan (314)
Minnesota (572)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (122)
New Hampshire (60)
New Jersey (2688)
New Mexico (12)
New York (2890)
North Carolina (1315)
North Dakota (4)
Northern California (6202)
Ohio (293)
Oklahoma (14)
Oregon (16)
Pennsylvania (2295)
Puerto Rico (21)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5129)
Tennessee (125)
Texas (1999)
United States (39969)
Utah (371)
Vermont (1)
Virginia (158)
Washington D.C. (38)
Washington State (955)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,938 Results for "omniseq inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
OmniSeq Receives New York State Approval for OmniSeq INSIGHT Genomic and Immune Profiling Test
OmniSeq®, an innovator in next generation sequencing in oncology, announced the New York State Department of Health’s Clinical Laboratory Evaluation Program has approved the OmniSeq INSIGHTSM test.
April 28, 2021
·
3 min read
Business
Labcorp And OmniSeq Launch INSIGHT℠, Next-Generation Sequencing Platform to Advance Precision Oncology
Labcorp (NYSE: LH), and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, today announced the launch of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology.
June 14, 2021
·
4 min read
BioMidwest
GenomOncology Pathology Workbench to Support OmniSeq INSIGHT℠, a Genomic and Immune Profiling Test That Identifies Potential Treatment and Clinical Trial Options for Solid Tumors
GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp’s OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors.
January 12, 2022
·
2 min read
Pharm Country
OmniSeq Receives ISO Certification for Quality Management Systems
OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the company has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management Systems (QMS)
December 1, 2020
·
2 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
Allumiqs Solutions Inc. and Allumiqs Corporation
September 15, 2026
·
1 min read
Drug Development
OmniSeq and UPMC Collaborate to Launch Novel Phase II Prospective Head and Neck Cancer Clinical Study
OmniSeq®, an innovator in next generation sequencing in oncology, today announced its collaboration with the University of Pittsburgh Medical Center (UPMC) to employ its RNA sequencing (RNA-seq) gene expression profile assay for selecting immunotherapy combinations for patients in a Phase II clinical trial for patients with Recurrent/Metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
January 28, 2021
·
2 min read
Press Releases
Carlsmed, Inc. Announces Chief Operating Officer Appointment
September 8, 2026
·
2 min read
Drug Development
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
OmniSeq, Inc.® announced it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial
August 3, 2018
·
4 min read
Pharm Country
OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify Patients Eligible for New, Targeted Therapy for Lung and Thyroid Cancer
OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance® comprehensive genomic and immune profiling assay to detect the presence of rare alterations in the RET gene in the tumors of some patients with non-small cell lung cancer (NSCLC) and thyroid cancer
June 29, 2020
·
3 min read
1 of 48,594
Next
